ArticleThe Journal of clinical investigation2023

Cotargeting a MYC/eIF4A-survival axis improves the efficacy of KRAS inhibitors in lung cancer.

Francesca Nardi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.